Traditional methods of controlling malaria with insecticides and parasiticides have been inadequate. The use of hybridoma and recombinant DNA technologies to study the malaria parasite has permitted the identification of several antigens which may elicit protective immune responses. Clincial trials have begun to evaluate the merits of these molecules as vaccine candidates. It is hoped that their large scale production in genetically engineered hosts will result in the development of an effective vaccine.
ASJC Scopus subject areas